Physician profile
Albert Rozo
NPI 1295796464
$3,221.33
in general payments reported to CMS, 2019-2025
27 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $557 · 2021: $756 · 2022: $330 · 2023: $387 · 2024: $510 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,465.29 | 2019-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $308.44 | 2019-2021 | |
| Amarin Pharma, INC. | $283.97 | 2020-2022 | |
| Abbvie INC. | $171.27 | 2020-2023 | Creon, Linzess |
| Astrazeneca Pharmaceuticals LP | $147.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $124.46 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $92.19 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.67 | 2020-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $59.17 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $58.68 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $53.17 | 2024 | Voquezna |
| Ardelyx, INC. | $46.97 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.59 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $36.97 | 2019-2022 | |
| Csl Behring | $27.30 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $27.00 | 2020-2021 | |
| Oxford Immunotec USA INC | $23.23 | 2022 | |
| Biogen, INC. | $20.65 | 2020 | |
| Amgen INC. | $20.28 | 2025 | Repatha, Otezla |
| Shire North American Group INC | $20.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.10 | 2019 | |
| Daiichi Sankyo INC. | $19.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.24 | 2020 | |
| Astellas Pharma US INC | $17.02 | 2019 | |
| Vistapharm, INC. | $14.51 | 2021 | |
| Medtronic, INC. | $13.21 | 2021 | |
| Althera Pharmaceuticals LLC | $10.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Rozo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.